Trials / Completed
CompletedNCT00167999
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | piperacillin-tazobactam |
Timeline
- Start date
- 2005-02-01
- First posted
- 2005-09-14
- Last updated
- 2007-03-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00167999. Inclusion in this directory is not an endorsement.